Clozapine-olanzapine: A potentially dangerous switch. A report of two cases

Journal of Clinical Pharmacy and Therapeutics

Volumn 24, Issue 3, 1999, Pages 191-195

  Delassus Guenault, N ^a   Jegouzo, A ^a   Odou, P ^a   Seguret, T ^a   Zangerlin, H ^a   Vignole, E ^a   Robert, H ^a  

^a EPSM Lille Metropole   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; MUSCARINIC RECEPTOR; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

ADULT; AGITATION; ANXIETY; ARTICLE; BRONCHUS OBSTRUCTION; CASE REPORT; DIAPHORESIS; DISEASE SEVERITY; ENURESIS; HOSPITALIZATION; HUMAN; HYPERSALIVATION; LUNG DISEASE; MALE; PATHOPHYSIOLOGY; REBOUND; RECEPTOR AFFINITY; SCHIZOPHRENIA; SUPERINFECTION; SUPERSENSITIVITY; SYMPTOMATOLOGY; WEANING; WITHDRAWAL SYNDROME;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CLOZAPINE; HUMANS; MALE; MIDDLE AGED; PIRENZEPINE; RECEPTORS, MUSCARINIC; SCHIZOPHRENIA; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 0032816907     PISSN: 02694727     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2710.1999.00218.x     Document Type: Article

References (18)

1. Jablensky A. (1986) Epidemiology of schizophrenia: a European perspective. Schizophrenia Bulletin, 12, 52-73.
2. Borison RL. (1996) Changing antipsychotic medication: guidelines on the transition to treatment with risperidone. Clinical Therapeutics, 18, 592-607.
3. American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders. 4th edn. Washington DC: American Psychiatric Association, 130-132.
4. Schwartz J, Brotman A. (1992) A clinical guide to antipsychotic drugs. Drugs, 6, 981-992.
5. Snyder SH. (1981) Dopamine receptor, neuroleptics and schizophrenia. American Journal of Psychiatry, 138, 460-464.
6. Kane J, Honigfeld G, Singer J, Meltzer H. (1988) Clozapine for treatment resistant schizophrenia. Archives of General Psychiatry, 45, 789-796.
7. Bymaster FP, Calligaro DO, Falcone JF, et al. (1996) Radio-receptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology, 14, 87-96.
8. Bymaster FP, Rasmussen K, Calligaro DO, et al. (1997) In vitro and in vivo biochemistry of Olanzapine: a novel, atypical antipsychotic drug. The Journal of Clinical Psychiatry, 58, 28-36.
9. Jones BD. (1996) Clinical experience with risperidone. The Journal of Clinical Psychiatry, 14, 25-29.
10. Borison RL, Diamond BI, Sinha D, et al. (1988) Clozapine withdrawal rebound psychosis. Psychopharmacoly, 24, 260-263.
11. Stanilla JK, DeLeon MD, Simpson GM. (1997) Clozapine withdrawal resulting in delirium with psychosis: a report of three cases. The Journal of Clinical Psychiatry, 58, 252-255.
12. Still D, Dorson P, Crismon L, Pousson C. (1996) Effects of switching inpatients with treatment resistant schizophrenia from clozapine to risperidone. Psychiatric Services, 12, 1382-1384.
13. Staedt J, Stoppe G, Hajak G, et al. (1996) Rebound insomnia after abrupt clozapine withdrawal. European Archives of Psychiatry and Clinical Neuroscience, 246, 79-82.
14. Malhotra A, Litman R, Pickar D. (1993) Adverse effects of antipsychotic drugs. Drugs Safety, 6, 429-436.
15. Verghese C, DeLeon J, Nair C, et al. (1996) Clozapine withdrawal effects and receptor profiles of typical and atypical antipsychotics. Biological Psychiatry, 39, 135-138.
16. Shiovitz TP, Welke TL, Tigel PD, et al. (1996) Cholinergic rebound and rapid onset psychosis following abrupt clozapine withdrawal. Schizophrenia Bulletin, 22, 591-595.
17. Parsa MAP, Al-Lahham YM, Meltzer LF (1993) Prolonged psychotic relapse after abrupt clozapine withdrawal. The Journal of Clinical Psychopharmacology, 13, 154-155.
18. De Leon J, Stanilla JK, Odom White A, et al. (1994) Anticholinergics to treat Clozapine withdrawal. The Journal of Clinical Psychiatry, 55, 119-120.